Waldencast's Beauty Empire Crumbles: Milk Makeup Sales Fall Amid Nasdaq Exit
Waldencast is rebranding to Milk Makeup plc and delisting from Nasdaq after selling Obagi Medical, while Milk's first-half sales fell 57.1% to $26.1 million.
Waldencast Acquisition Corp, launched in early 2021 by former L’Oréal executives Michel Brousset and Hind Sebti as a special purpose acquisition company, is reshaping its operations following a dramatic contraction of its multibrand strategy, according to Fortune. In November 2021, Waldencast announced a $1.2 billion three-way business combination with Obagi Medical and Milk Makeup, closing the transaction in July 2022 as the initial step toward building a global beauty and wellness platform.
That structure has largely unwound. In June, Waldencast agreed to sell Obagi Medical to private equity firm Bridgepoint in a deal closing on July 30 for up to $460 million, which included vendor notes and up to $64 million in earnout payments tied to future performance, Fortune reported. Waldencast previously valued Obagi at $858 million on an enterprise-value basis in 2021. Furthermore, the company parted with Obagi's operations in Japan through a transaction with Rohto Pharmaceutical near the end of 2025.
Three senior executives, including Brousset, Sebti, and CFO Manuel Manfredi, departed Waldencast to lead Obagi alongside Bridgepoint, leaving executive chairman Felipe Dutra as principal executive and financial officer, according to Fortune. Four days prior to publishing its first-half results on September 28, Waldencast filed a Form 25 to voluntarily delist from Nasdaq, anticipating its last day of trading on or about October 2 and planning an over-the-counter quotation under the ticker “MLKM.”
The transition leaves Waldencast solely focused on Milk Makeup, whose financial performance has deteriorated sharply, Fortune reported. Milk Makeup’s net revenue fell 57.1% to $26.1 million in the first half of 2026 compared to $60.9 million the previous year, a period that included roughly $10 million in non-recurring pipeline shipments. The brand also swung to an adjusted EBITDA loss of $14.8 million from a profit of $9.7 million, with Waldencast noting the results largely reflect decisions made in 2025.
Reflecting diminished expectations, Waldencast recorded a $52.3 million noncash goodwill impairment charge on Milk in the first-half results, following a $20 million impairment a year earlier, according to Fortune. The latest write-down reduced Milk-related goodwill on the balance sheet from $115.1 million to $62.8 million. Based on impairment test disclosures, the company's base estimate for the Milk reporting unit's fair value comes out to roughly $180 million.
To counter the decline, Waldencast is returning to the brand's roots, naming cofounder Mazdack Rassi as president in November 2025 alongside cofounder Zanna Roberts Rassi to oversee creative direction and product vision, Fortune reported. Subject to shareholder approval, Waldencast intends to rename itself Milk Makeup plc. Financially, the company reported $138.6 million in cash as of August 31 after using Obagi sale proceeds to repay $178.4 million in debt.